News & Resources
Warning: is_a() expects parameter 2 to be string, object given in /home/customer/www/aperturagtx.com/public_html/wp-content/themes/apertura/template-parts/content.php on line 19
Apertura Gene Therapy Announces Scientific Founder Presentations on AAV Capsid Engineering Platforms at ASGCT 2023 Annual Meeting
Uncategorized
NEW YORK and CAMBRIDGE, Mass., May 3, 2023 – Apertura Gene Therapy, a biotechnology company opening opportunities in genetic medicine for treating debilitating diseases with limited options, today announced that academic collaborator and scientific co-founder, Ben Deverman, PhD, Senior Director of Vector Engineering and Institute Scientist at the Broad Institute of MIT and Harvard, will present at […]
Read More
Apertura Appoints Gene Therapy Executive Joseph La Barge as Chief Executive Officer
Uncategorized
Apertura Gene Therapy announced the appointment of gene therapy executive Joseph La Barge as Chief Executive Officer.
Read More
Apertura Announces Fit4Function AAV Capsid Engineering Platform and In Vivo Proof-of-Concept Data to Be Presented at the 25ᵗʰ Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Uncategorized
NEW YORK and CAMBRIDGE, Mass., May 4, 2022 – Apertura Gene Therapy, a biotechnology company opening opportunities for treating debilitating diseases with limited options for patients, today announced that its academic collaborators will present findings on the Fit4Function AAV capsid engineering platform and non-human primate proof-of-concept data at the 25th Annual Meeting of the American Society of […]
Read More
Apertura Gene Therapy Launches with $67M Series A Financing from Deerfield and an Innovative Technology Platform to Develop Genetic Medicines
Uncategorized
Founded on platform technologies developed by Broad Institute of MIT and Harvard and Harvard Medical School Investigators
Read More